Lynparza Approved in U.S. as First-line Maintenance Therapy for BRCA-positive Advanced Ovarian Cancer

Lynparza Approved in U.S. as First-line Maintenance Therapy for BRCA-positive Advanced Ovarian Cancer
Women with BRCA-mutated advanced ovarian cancer living in the United States can now receive Lynparza (olaparib), developed by AstraZeneca and Merck, as a maintenance treatment for their partial or complete response to first-line platinum-based chemotherapy. The U.S. Food and Drug Administration's decision makes Lynparza the first PARP inhibitor to be approved as a first-line maintenance therapy for BRCA-mutated advanced ovarian cancer. “Women with ovarian cancer are often first diagnosed with advanced disease, which is associated with poor outcomes," Dave Fredrickson, executive vice president and head of the oncology business unit at AstraZeneca, said in a press release. "[This] approval is a critical advancement and brings us closer to our goal of helping these patients achieve long-term remission.” The faster division rate of cancer cells makes them accumulate errors faster than healthy cells. Lynparza, a PARP enzyme inhibitor, was designed to prevent cancer cells from repairing their DNA errors, which eventually causes them to die. The therapy is particularly effective in cancers with mutations in DNA-repairing genes, such as BRCA1 and BRCA2
Subscribe or to access all post and page content.